Please login to the form below
QMF149
This page shows the latest QMF149 news and features for those working in and with pharma, biotech and healthcare.
Novartis reveals full phase 3 results for Enerzair Breezhaler
function compared to treatment with once-daily QMF149 (indacaterol acetate and mometasone furoate). ... The overall occurrence of adverse events and serious adverse events for both Enerzair Breezhaler and QMF149 in the study were generally low and
Latest news
-
Novartis strengthens case for its combination asthma drug
The asthma combination regimen, QMF149, is a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate. ... QMF149 also met the secondary endpoint of the study, demonstrating a statistically significant improvement in asthma
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
